← Eichor
Condition: Untreated Aml Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Untreated Aml

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With A
Phase 2 · 19 location(s) · Shanghai Tong Ren Hospital · NCT05736965Veneclax, Chidaniline Combined With Azacitidine Followed by Decitabine + MAG Regimen in the Treatment of Elderly Untreat
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT06827899A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leuk
Phase 2 · 32 location(s) · Stemline Therapeutics, Inc. · NCT06456463Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML
Phase 3 · 48 location(s) · Gruppo Italiano Malattie EMatologiche dell'Adulto · NCT04168502Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Phase 3 · 106 location(s) · Kura Oncology, Inc. · NCT07007312A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax,
Phase 1 · 44 location(s) · Kura Oncology, Inc. · NCT05735184Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysp
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT02115295Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
Phase 1/Phase 2 · 19 location(s) · Beat AML, LLC · NCT03013998Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) o
Phase 4 · 11 location(s) · AbbVie · NCT07044687Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloi
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT03586609Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Pati
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT00801489Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Phase 1 · 30 location(s) · Institut de Recherches Internationales Servier · NCT020748393'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090Oral-ATO for TP53-mutated Myeloid Malignancies
Phase 2 · 1 location(s) · The University of Hong Kong · NCT06778187Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results
Phase 2 · 4 location(s) · Shanghai Tong Ren Hospital · NCT05736978Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT01515527VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial
Phase 2 · 1 location(s) · Beijing 302 Hospital · NCT07514832Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Phase N/A · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137643Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untre
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT03629171Venetoclax-Decitabine in Untreated Elderly/Unfit AML
NA · 1 location(s) · The Second Hospital of Hebei Medical University · NCT07117422Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia
Phase 2 · 222 location(s) · National Cancer Institute (NCI) · NCT05554406
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.